Onclive articles Copyright (c) 2014 Intellisphere, LLC. All rights reserved. http://www.onclive.com/articles Onclive articles Onclive articles en-us Tue, 28 Apr 2015 06:48:36 UTC 5 Onclive articles 144 47 http://www.onclive.com/articles http://www.onclive.com/media/image/35ab4bcc0544887940a968b55494cbb1.jpg <![CDATA[Ofatumumab/Chemo Combination Delays Progression in CLL]]>http://www.onclive.com/web-exclusives/OfatumumabChemo-Combination-Delays-Progression-in-CLLOnclive articlesusMon, 27 Apr 2015 22:37:00 UTCOnclive<![CDATA[Dense Breasts Found in More Black Than White Women, Risk Could Help Target Cancer]]>http://www.onclive.com/web-exclusives/Dense-Breasts-Found-in-More-Black-Than-White-Women-Risk-Could-Help-Target-CancerOnclive articlesusMon, 27 Apr 2015 21:25:00 UTCOnclive<![CDATA[FDA Approval Sought for MM-398 in Advanced Pancreatic Cancer]]>http://www.onclive.com/web-exclusives/FDA-Approval-Sought-for-MM-398-in-Advanced-Pancreatic-CancerOnclive articlesusMon, 27 Apr 2015 13:49:00 UTCOnclive<![CDATA[Mission to Treat Rural Poor Is Challenged by Merger Pressure]]>http://www.onclive.com/publications/oncology-business-news/2015/May-2015/Mission-to-Treat-Rural-Poor-is-Challenged-by-Merger-PressureOnclive articlesusSun, 26 Apr 2015 16:00:00 UTCOnclive<![CDATA[Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma ]]>http://www.onclive.com/web-exclusives/Hodi-Speaks-to-Significance-of-Phase-II-Data-on-Ipilimumab-Plus-Nivolumab-in-Melanoma Onclive articlesusSat, 25 Apr 2015 16:00:00 UTCOnclive<![CDATA[Generic Chemotherapies Recalled by Manufacturer]]>http://www.onclive.com/web-exclusives/Generic-Chemotherapies-Recalled-by-ManufacturerOnclive articlesusSat, 25 Apr 2015 15:09:00 UTCOnclive<![CDATA[CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL]]>http://www.onclive.com/web-exclusives/CAR-T-Cell-Therapy-Surpasses-90-Complete-Remission-Rate-in-Pediatric-ALLOnclive articlesusFri, 24 Apr 2015 18:35:00 UTCOnclive<![CDATA[FDA Approves Second-Line Ramucirumab for mCRC]]>http://www.onclive.com/web-exclusives/FDA-Approves-Second-Line-Ramucirumab-for-mCRCOnclive articlesusFri, 24 Apr 2015 18:33:00 UTCOnclive<![CDATA[FDA Updates Pomalidomide Multiple Myeloma Label]]>http://www.onclive.com/web-exclusives/FDA-Updates-Pomalidomide-Multiple-Myeloma-LabelOnclive articlesusFri, 24 Apr 2015 16:23:00 UTCOnclive<![CDATA[Ibrutinib Response Rates Improve With Longer Follow-Up in CLL]]>http://www.onclive.com/web-exclusives/Ibrutinib-Response-Rates-Improve-With-Longer-Follow-Up-in-CLLOnclive articlesusFri, 24 Apr 2015 15:18:00 UTCOnclive